OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in…
Adjust this page to suit you. Your choices are saved in this browser.
Cookies. Chipokia uses one cookie, and only if you allow it: a random ID so your up and down votes stay yours. No analytics, no advertising, no tracking of any kind. Privacy & Cookie Policy.
